Drug Patent Watch

JANUARY 13, 2025

The Rise of Biosimilars: A Healthcare Revolution Biosimilars, often referred to as the “generic equivalents” of biologic drugs, have been making waves in the pharmaceutical industry for over a decade. ”[1] The global biosimilars market is experiencing exponential growth, with projections indicating it will reach $69.4

Marketing 78

Marketing Insulin Generic Drugs Medicine 78

XTalks

MARCH 15, 2024

LillyDirect Pharmacy Solutions, Eli Lilly’s direct-to-consumer (DTC) drugs website, is teaming up with Amazon Pharmacy to deliver select medications to people’s homes. The drugs include Lilly’s newly approved GLP-1 obesity drug Zepbound (tirzepatide), around a dozen of the company’s insulins and migraine drug Emgality (galcanezumab).

Pharmacy 111

Pharmacy Drugs Insulin Branding 111

Pharmaceutical Technology

DECEMBER 4, 2022

It is all about what you can get at the lowest cost,” says Dr. Raymond Cross, director of the inflammatory bowel disease program at University of Maryland’s School of Medicine, Baltimore. For example, the first-to-market status was beneficial when it came to insulin biosimilars. …[but] for biosimilars, it is all about the money.

Marketing 262

Marketing Pharmacy Production Branding 262

XTalks

AUGUST 2, 2023

With each passing year, pharmaceutical companies around the globe strive to deliver cutting-edge medicines, therapies and vaccines that impact the lives of millions. In this in-depth article, we embark on a captivating journey to uncover the top 30 pharma and biotech companies that have been instrumental in shaping the future of medicine.

Sales 98

Sales Manufacturing FDA Approval Life Science 98

pharmaphorum

MARCH 3, 2022

Non-profit drugmaker Civica Rx has said it will launch biosimilars of three big-selling insulin products in the US by 2024 to help diabetic patients struggling with the cost of the drugs. Cheaper options are meanwhile becoming available.

Insulin 52

Insulin Production Generic Drugs Medicine 52

pharmaphorum

MARCH 23, 2022

The US Senate will vote in the coming weeks on whether to introduce a $35 cap on the monthly cost of insulin to patients that was endorsed by President Joe Biden in his 2022 State of the Union address. Assuming the bill is later passed by the Senate and signed into law by President Biden, the insulin cap would take effect beginning in 2023.

Insulin 75

Insulin Production Generic Drugs FDA Approval 75

Pharmacy Checkers

MARCH 11, 2020

tolerates this magnitude of cost-related medication non-adherence, in which people die because of drug prices, should shock our national conscience. [2]. 381), if their imported prescription orders are refused so that they are released to those patients who provide ample evidence to the FDA that their medicine is not an unreasonable risk.

Pharmacy 41

Pharmacy Drugs FDA Approval Licensing 41